← Markets
FDA moves BPC-157 to Category 1 by…?

FDA moves BPC-157 to Category 1 by…?

Resolves Dec 31, 2026·$115 24h vol·politics
$1.1k total volume·Open for 19 days

December 31, 2026

42%-6.5%
OutcomeYesNo
December 31, 2026
August 31, 2026

Order Book

December 31, 2026

PriceSharesTotal
94.0¢8$8
90.0¢2.0k$1.8k
88.0¢2.3k$2.0k
84.0¢450$378
60.0¢100$60
59.0¢200$118
55.0¢27$15
54.0¢8$4
53.0¢30$16
52.0¢7$4
48.0¢last trade
21.0¢ spread
31.0¢38$12
30.0¢60$18
16.0¢70$11
6.0¢10$1
5.0¢760$38
4.0¢1.1k$43
3.0¢2.1k$64
2.0¢2.9k$59
1.0¢6.5k$65
$310 bids$4.4k asks

Resolution Criteria

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

December 31, 2026

42%